next agonist
The prevention-trial problem: why 'stops skin cancer' is so hard to prove
Analysis. Assume, for this piece, that the chemistry problem is already solved — that a clean, MC1R-selective, safe-seeming photoprotective molecule exists. It could still never reach you, because the thing standing in the way isn’t the molecule. It’s the trial.
Prevention is the hardest claim in medicine to prove
Treating a disease hands you a fast, visible endpoint: the patient hurts less, the lesion shrinks, the number moves within months. Preventing a disease hands you the absence of an event that was going to happen years from now, in only some people, and asks you to prove the absence was your doing.
To show a drug prevents melanoma or other skin cancers, you enroll an enormous number of healthy people, give half of them the drug, and follow everyone for years — long enough for a real gap in cancer rates to open between the two groups. Big cohort, long horizon, a rare-ish endpoint: that combination is one of the most expensive shapes a clinical trial can take.
The contrast with the approved melanocortin drug is stark. Afamelanotide cleared trials for a rare light-sensitivity disease where the endpoint — pain-free time under light — appears in weeks (the middle-ground agonist already exists). Same class of molecule; incomparably easier proof. The disease was the easy customer. Prevention is the hard one.
The risk bar moves the wrong way
The healthier the population, the less risk a regulator will tolerate — and reasonably so, because you’re dosing people who aren’t sick. Medicine’s history is unkind to lifestyle drugs handed broadly to well people and later found to carry rare but serious harms. A prevention drug has to be not merely effective over a decade but clean over a decade, across millions of users, and be shown to be. The safety burden scales with the size of the healthy population you hope to reach.
The surrogate shortcut, and its catch
There are faster proxies a program might lean on: reductions in ultraviolet- induced DNA damage, in actinic skin changes, in how readily skin burns. Good surrogates could de-risk a program and shorten its early phases.
But regulators are justifiably wary of surrogate endpoints for cancer prevention, because a drug can move a proxy without moving the outcome that actually matters to a patient. Sooner or later, for a claim this consequential, someone has to run the long, real study. The shortcut can start the journey; it can’t finish it.
Why it isn’t hopeless
Medicine does eventually clear bars exactly this high — when the market at the top is big enough to pay for the climb. Statins earned their long cardiovascular outcome trials. GLP-1 drugs earned the cardiovascular and weight-outcome data that turned a diabetes treatment into a blockbuster for a vastly larger population. In each case a sponsor chose to fund the mountain because the payoff justified it.
Photoprotection’s mountain is the same shape and the same height. What it’s waiting for is the same decision: someone concluding that the population at the summit is worth the expedition. The most realistic way that decision gets made isn’t one heroic leap — it’s a series of smaller, fundable steps (the beachhead indications).